Q-omics provides the consensus-scored THUMPD1 profile across patient tissues and cancer cell-line models. THUMPD1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, THUMPD1 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, THUMPD1 protein abundance shows 26,446 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where THUMPD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THUMPD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THUMPD1 survival associations across molecular data types. THUMPD1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THUMPD1 RNA expression–survival associations across cancer types. High THUMPD1 expression shows unfavorable associations in SCLC, but favorable associations in KIRC, SKCM, ACC, READ and LAML. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for THUMPD1 RNA expression.
This table summarizes THUMPD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for THUMPD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THUMPD1 shows lower tumor expression in THCA, UCEC and KICH and higher tumor expression in LIHC, KIRP and HNSC. The THCA box plot shows higher THUMPD1 RNA expression in normal versus tumor tissue (log2 FC = −1.004, t-test p < 0.001).
This table shows molecular features associated with THUMPD1 in patient tissues and cancer cell lines. In patient samples, THUMPD1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, THUMPD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
